CHICAGO, IL—An investigational agent given by subcutaneous injection can drastically reduce levels of lipoprotein(a), with sustained effects seen out to about 1.5 years, according to data from the ...

The phase 2 ALPACA trial of lepodisiran (Eli Lilly), presented at the American College of Cardiology Scientific Session and simultaneously published in The New England Journal of Medicine ...